Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis
Haim Leibovitzh, Sun-Ho Lee, Juan A. Raygoza Garay, et al.
Gut (2023) Vol. 72, Iss. 8, pp. 1462-1471
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Deciphering the different phases of preclinical inflammatory bowel disease
Jonas J. Rudbaek, Manasi Agrawal, Joana Torres, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 2, pp. 86-100
Open Access | Times Cited: 45
Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia
Marietta Iacucci, Giovanni Santacroce, Snehali Majumder, et al.
Gut (2024) Vol. 73, Iss. 10, pp. 1749-1762
Open Access | Times Cited: 19
Inflammation, Autoinflammation and Autoimmunity in Inflammatory Bowel Diseases
Andrea Padoan, Giulia Musso, Nicole Contran, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 7, pp. 5534-5557
Open Access | Times Cited: 33
Challenges in IBD Research 2024: Precision Medicine
Sana Syed, Brigid S. Boland, Lauren T Bourke, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S39-S54
Open Access | Times Cited: 10
Review article: Prevention of inflammatory bowel disease—The path forward
Sérgio Bronze, Manasi Agrawal, Jean‐Frédéric Colombel, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1166-1175
Closed Access | Times Cited: 9
Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease
Yiran Zhang, John P. Thomas, Tamás Korcsmáros, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101738-101738
Open Access | Times Cited: 8
Butyrate: a bridge between intestinal flora and rheumatoid arthritis
Cao Yang, Jingjing Chen, Jing Xiao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms
Yijing Peng, Yizhe Ma, Zichen Luo, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 16
Challenges in IBD Research 2024: Environmental Triggers
Ashwin N. Ananthakrishnan, Konstantinos Gerasimidis, Shuk-Mei Ho, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S19-S29
Open Access | Times Cited: 5
Challenges in IBD Research 2024: Preclinical Human IBD Mechanisms
Matthew A. Ciorba, Liza Konnikova, Simon A. Hirota, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S5-S18
Open Access | Times Cited: 5
Magnolin inhibits intestinal epithelial cell apoptosis alleviating Crohn's disease-like colitis by suppressing the PI3K/AKT signalling pathway
Min Zhang, Xue Song, Shengbao Liu, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112181-112181
Open Access | Times Cited: 4
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
Xiaojing Xu, Luoyan Ai, Keshu Hu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Genetic and environmental factors influencing Crohn’s disease
Ye-Hui Fan, Mingwei Wang, Yubo Gao, et al.
World Journal of Gastrointestinal Surgery (2025) Vol. 17, Iss. 3
Closed Access
Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission
Katie A. Dunleavy, Chad R Rypstra, Irene Busciglio, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
First-in-Human Assessment of Gut Permeability in Crohn’s Disease Patients Using Fluorophore Technology
Lori R. Holtz, Billy D. Nix, Sewuese E. Akuse, et al.
Gastro Hep Advances (2024) Vol. 3, Iss. 4, pp. 491-497
Open Access | Times Cited: 3
Intestinal Inflammation and Extraintestinal Disease: Understanding Dynamic Risk
James J. Ashton, Jack Satsangi, Holm H. Uhlig
Gastroenterology (2024) Vol. 167, Iss. 2, pp. 205-208
Open Access | Times Cited: 3
Prediction and Prevention of Inflammatory Bowel Disease
Emily W. Lopes, Williams Turpin, Kenneth Croitoru, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 396-405.e1
Closed Access | Times Cited: 3
A spotlight on intestinal permeability and inflammatory bowel diseases
Timo Räth, Raja Atreya, Markus F. Neurath
Expert Review of Gastroenterology & Hepatology (2023) Vol. 17, Iss. 9, pp. 893-902
Closed Access | Times Cited: 8
Defining Biological Remission in Crohn’s Disease: Interest, Challenges and Future Directions
Nicolas Pierre, Sophie Vieujean, Laurent Peyrin‐Biroulet, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 10, pp. 1698-1702
Open Access | Times Cited: 7
Analysis of the interferon-γ-induced secretome of intestinal endothelial cells: putative impact on epithelial barrier dysfunction in IBD
Elisabeth Naschberger, Christian Flierl, Jing‐Hao Huang, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 7
Explore key genes of Crohn’s disease based on glycerophospholipid metabolism: A comprehensive analysis Utilizing Mendelian Randomization, Multi-Omics integration, Machine Learning, and SHAP methodology
Changan Chen, Juan‐Hua Quan, Xintian Chen, et al.
International Immunopharmacology (2024) Vol. 141, pp. 112905-112905
Closed Access | Times Cited: 2
Healthy first-degree relatives from multiplex families versus simplex families have a higher subclinical intestinal inflammation, a distinct fecal microbial signature, and harbor a higher risk of developing Crohn’s disease
Pablo A. Olivera, Helena Martínez-Lozano, Haim Leibovitzh, et al.
Gastroenterology (2024)
Open Access | Times Cited: 2
Identification of CCL20 as a Prognostic Predictor for Severe Fever With Thrombocytopenia Syndrome Based on Plasma Proteomics
Yue Zhang, Li Lan, Yuanni Liu, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 3, pp. 741-753
Closed Access | Times Cited: 2
Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study
Jiangwei Sun, Jialu Yao, Ola Olén, et al.
Gut (2024) Vol. 73, Iss. 11, pp. e23-e23
Closed Access | Times Cited: 1
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab
Nicolas Pierre, Vân Anh Huynh‐Thu, Dominique Baiwir, et al.
Gut (2024), pp. gutjnl-332648
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top